| Objective:To investigate the molecular mechanism of Progynova in IVF-ET. Methods:1. During long term protocol of IVF-ET cycle, 131 infertility patients who underwent the controlled ovarian hyperstimulation and signed informed consent were analyzed.2. They were divided into three groups according to the basic ovarian score system, and taken different dosages of Progynova from the date of Gn.3. Collected FF after retrieval oocyte and centrifugated at 3000r/min for 10 minutes, the supernatants were stored at -20℃.4. In vitro oocyte were cultured for 46 hours, then took IVF or ICSI. Embryos were generally transferred to the uterus 3 days after oocyte retrieval. All patients received luteal support.5. In present study, TGF-a, E2 and P in FF were measured by RIA for analysis and laborary indexes;The comparison of the effect on serum sex hormone among different groups were performed;In addition, including pregnancy rate.Results:There are no significant differences in serum E2 and P, the rate of MII oocyte, fertilization and cleavage rate (p>0.05). Among groups, the amounts of gonadotropin, the days of ovarian hyperstimulation, the rate of oocyte retrieval, implantation rate and TGF-ain FF have significant differences (p<0.05). The level of E2 and P in FF have no significant differences between group A and B, but compared with group C both is reverse.In addition, TGF-ais negative correlation with P in FF, R=-0.319 (P<0.05) , and positive correlation with the endometrial thickness, R=0.195 (p<0.05), but has no correlation with E2.For clinical pregnancy rate, there are no significant differences between patients withProgynova and those of controlled group, but is tendency to increase. Conclusion:In COH, the use of Progynova may be positive according to the basic ovarian status. By TGF-ain FF, it can improve oocyte quality, increasing endometrial thickness as well as implantation and clinical pregnancy rate, but no effect of serum hormone.
|
PDF Full Text Request